Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab

NCT02138617 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT02138617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02138617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2014
Completion date
August 1, 2024
Enrollment
100 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer